Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of QLM3003 Ointment in Mild to Moderate Atopic Dermatitis
NCT06880276Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2025
- Primary completion
- Mar 2027
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of QLM3003 in atopic dermatitis (AD), sponsored by Qilu Pharmaceutical. Started May 2025; status: recruiting.
02
Drugs
QLM3003
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06880276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06880276.